Knowledge Distillery

Platelets represent a potential therapeutic target for improved clinical outcomes in patients with COVID-19. The objective of this study was to…

In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load…

Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge; the role of extended thromboprophylaxis in this population is…

Dysregulated inflammation is associated with poor outcomes in COVID-19. In this study the authors aimed to assess the efficacy of namilumab (a…

In this paper, just published in Lancet, the authors performed a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of a…

In this open-label, multicentre, randomised clinical trial, recently published in JAMA, the authors evaluate the efficacy and adverse effects of…

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S COVID-19 Vaccine

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of COVID-19

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID…

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial